PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

被引：0

作者：

McDonald, F. ^{[1
]}

Mornex, F. ^{[2
]}

Garassino, M. C. ^{[3
]}

Filippi, A. R. ^{[4
,5
]}

Christoph, D. ^{[6
]}

Haakensen, V. D. ^{[7
]}

Agbarya, A. ^{[8
]}

Van den Heuvel, M. ^{[9
]}

Vercauter, P. ^{[10
]}

Chouaid, C. ^{[11
]}

Pichon, E. ^{[12
]}

Siva, S. ^{[13
]}

Steinbusch, L. ^{[9
]}

Peretz, I. ^{[14
]}

Solomon, B. ^{[15
]}

Decoster, L. ^{[16
]}

Sawyer, W. ^{[17
]}

Allen, A. ^{[18
]}

Licour, M. ^{[19
]}

Girard, N. ^{[20
,21
]}

机构：

[1] Royal Marsden Hosp NHS Fdn Trust, Lung Unit, London, England

[2] Ctr Hosp Univ Lyon, Dept Radiat Oncol, Lyon, France

[3] Ist Nazl Tumori Milano Fdn IRCCS, Div Med Oncol, Milan, Italy

[4] Fdn IRCCS Policlin San Matteo, Dept Radiat Oncol, Pavia, Italy

[5] Univ Pavia, Pavia, Italy

[6] Evangel Kliniken Essen Mitte, Dept Med Oncol, Evangel Huyssens Stiftung, Essen, Germany

[7] Oslo Univ Hosp, Dept Oncol, Oslo, Norway

[8] Bney Zion Med Ctr, Dept Oncol, Haifa, Israel

[9] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands

[10] Onze Lieve Vrouw Ziekenhuis Aalst, Dept Pneumol, Aalst, Belgium

[11] CHI Creteil, Serv Pneumol, Creteil, France

[12] CHRU Tours, Serv Pneumol, Hop Bretonneau, Tours, France

[13] Sir Peter MacCallum Canc Ctr, Dept Oncol, Melbourne, Australia

[14] Clalit Hlth Serv, Inst Oncol, Tel Aviv, Israel

[15] Univ Melbourne, Sir Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Australia

[16] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Dept Med Oncol, Brussels, Belgium

[17] AstraZeneca, Cambridge, England

[18] AstraZeneca, Gaithersburg, MD USA

[19] Astrazeneca, Paris, France

[20] Inst Curie, Inst Thorax, Paris, France

[21] Montsouris, Paris, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

79MO

引用

页码：S738 / S739

页数：2

共 50 条

[31] Real-world Survival with CRT plus durvalumab for Unresectable, Stage III NSCLC in Canada: the RELEVANCE Study
Wheatley-Price, P.
Navani, V.
Pabani, A.
Routy, B.
Snow, S.
Denault, M. -H.
Kim, Y.
Syed, I.
Devost, N.
Hui, D.
Arora, P.
Velummailum, R.
Springford, A.
McKibbon, C.
Ho, C.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S159 - S159
[32] Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial"
Yu, Shaorong
Feng, Jifeng
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (01) : 173 - 174
[33] Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
Bischoff, Helge
Garassino, Marina Chiara
Mazieres, Julien
Reck, Martin
Chouaid, Christos
Cove-Smith, Laura
Mansy, Talal
Migliorino, Maria R.
Delmonte, Angelo
Garcia Sanchez, Jose
Chara Velarde, Luis Enrique
Bernabe, Reyes
Paz-Ares, Luis
Perez, Ignacio Diaz
Trunova, Nataliya
Foroutanpour, Kayhan
Faivre-Finn, Corinne
Reinmuth, Niels
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 160 - 161
[34] Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
Garassino, M. C.
Mazieres, J.
Reck, M.
Chouaid, C.
Bischoff, H.
Reinmuth, N.
Cove-Smith, L.
Mansy, T.
Cortinovis, D.
Migliorino, M. R.
Delmonte, A.
Sanchez, J. Garcia
Velarde, L. E. Chara
Bernabe, R.
Paz-Ares, L.
Perez, I. Diaz
Trunova, N.
Foroutanpour, K.
Faivre-Finn, C.
ANNALS OF ONCOLOGY, 2022, 33 : S81 - S82
[35] PACIFIC-6: A Phase II Study of Durvalumab Following Sequential Chemoradiotherapy in Patients with Stage III, Unresectable NSCLC
Garassino, M.
Faivre-Finn, C.
Mazieres, J.
Reck, M.
Emeribe, U.
Franks, A.
Trunova, N.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S403 - S404
[36] Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
Faivre-Finn, Corinne
Spigel, David R.
Senan, Suresh
Langer, Corey
Perez, Bradford A.
Ozguroglu, Mustafa
Daniel, Davey
Villegas, Augusto
Vicente, David
Hui, Rina
Murakami, Shuji
Paz-Ares, Luis
Broadhurst, Helen
Wadsworth, Catherine
Dennis, Phillip A.
Antonia, Scott J.
LUNG CANCER, 2021, 151 : 30 - 38
[37] PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT
Vansteenkiste, J.
Naidoo, J.
Faivre-Finn, C.
Ozguroglu, M.
Villegas, A.
Daniel, D.
Murakami, S.
Hui, R.
Lee, K.
Cho, B. C.
Kubota, K.
Poole, L.
Wadsworth, C.
Dennis, P.
Antonia, S.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S370 - S371
[38] First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC
Faehling, Martin
Planchard, David
Cho, Byoung Chul
Gray, Jhanelle Elaine
Paz-Ares, Luis G.
Ozguroglu, Mustafa
Villegas, Augusto E.
Daniels, Davey B.
Vicente, David
Murakami, Shuji
Hui, Rina
Kurata, Takayasu
Chiappori, Alberto
Lee, Ki Hyeong
Gu, Yu
Wadsworth, Catherine
Dennis, Phillip A.
Antonia, Scott Joseph
de Wit, Maike
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 120 - 120
[39] The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
Kim, Y.
Choi, Y-K
Kwak, Y-K
Lee, Y-H
Kim, S-H
Sung, S-Y
Son, S-H
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S281 - S281
[40] Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations
Cortiula, Francesco
De Ruysscher, Dirk
Steens, Michelle
Wijsman, Robin
van der Wekken, Anthonie
Alberti, Martina
Hendriks, Lizza E. L.
EUROPEAN JOURNAL OF CANCER, 2023, 184 : 172 - 178

← 1 2 3 4 5 →